University of Rochester

Speakers at this year's ABRF meeting described how they used single-cell tools in combination with other single-cell approaches and other methods.

The study will use Admera's PGxOne Plus test, which uses next-generation sequencing technology to interrogate genes in order to predict how patients will respond to drug therapy.

The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.

The medical center will provide samples from their patients and will have access to the company's clinical data and other biological samples.